21 Dec 2009
Shire Expands its Award-Winning ADHD Support Resource, ADHDSupport.com, by Launching an ADHD Twitter™ Page
PHILADELPHIA – December 21, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced the launch of its newest online Attention-Deficit/Hyperactivity Disorder (ADHD) resource, the ADHD Support Twitter™ page (http://twitter.com/adhdsupport), derived from the Shire award-winning online educational resource, ADHDSupport.com.
The social networking service Twitter, estimated to reach approximately six million unique monthly visitors, will enable Shire to stay connected by sending tweets from the ‘ADHD Support’ Twitter page (http://twitter.com/adhdsupport) to its followers. The tweets highlight the online resource ADHDSupport.com and will contain links that provide easy access to information about the evaluation process and management of the disorder. Additionally, Shire may tweet about the latest ADHD research, tips, resources, and events of interest to the ADHD community. Guest tweeters, including physicians, psychologists, or coaches who specialize in ADHD, may also be featured from time to time.
“Extending our ADHD resources through Twitter is part of the ongoing commitment of Shire to provide education and support to ADHD patients and caregivers,” says Michael Yasick, Senior Vice President of the ADHD Business Unit at Shire. “By providing access to information from ADHDSupport.com via Twitter, we are able to reach people who are looking for ADHD information in untraditional, yet increasingly popular places, like social networking sites.”
More than 60 million US adults use social media applications for health care and medical purposes. In fact, 34 percent of consumers have accessed social media for health- and wellness-related information over the past 12 months.
“As an active participant in social networking, I know first-hand that people are eagerly seeking information about ADHD online, including on blogs, forums, and social media sites,” said Michele Novotni, PhD, psychologist and consultant in the development of ADHDSupport.com. “ADHDSupport.com provides a resource for people who are impacted by ADHD, and tweeting information about the site, ADHD research, tips, resources, and events, is another way to provide information. Best of all, tweets are short and fast which is a real time saver on obtaining information on ADHD.”
For further information please contact:
|Media||Matthew Cabrey (Shire North America)||+1 484 595 8248|
|Kerri Thompson (Porter Novelli for Shire)||+1 212 601 8394|
ADHD is one of the most common psychiatric disorders in children and adolescents. Worldwide prevalence of ADHD is estimated at 5.3 percent (with large variability), according to a comprehensive systematic review of this topic published in 2007 in the American Journal of Psychiatry. In the United States, approximately 7.8 percent of all school-aged children, or about 4.4 million children aged 4 to 17 years, have been diagnosed with ADHD at some point in their lives, according to the Centers for Disease Control and Prevention (CDC). The disorder is also estimated to affect 4.4 percent of US adults aged 18 to 44 based on results from the National Comorbidity Survey Replication. When this percentage is extrapolated to the full US population aged 18 and over, almost 10 million adults are believed to have ADHD.
ADHD is a psychiatric behavioral disorder that manifests as a persistent pattern of inattention and/or hyperactivity-impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level of development. The specific etiology of ADHD is unknown and there is no single diagnostic test for this disorder. Adequate diagnosis requires the use of medical and special psychological, educational, and social resources, utilizing diagnostic criteria such as Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV®) or International Classification of Diseases 10 (ICD-10).
Although there is no cure for ADHD, there are accepted treatments that specifically target its symptoms. Standard treatments include educational approaches, psychological or behavioral modification, and/or medication.
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s Web site: http://www.shire.com/.
THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company’s results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company’s Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company’s products; the Company’s ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company’s products; the Company’s ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company’s ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company’s filings with the Securities and Exchange Commission.